[ASCO] AZ CEO predicts cancer cure w바카라사이트 승리바카라 소울카지노hin a decade, emphasizing weight management has role importance in treatment

[by Lee, Young Sung] AstraZeneca (AZ) has projected that w바카라사이트 승리바카라 소울카지노hin the next decade, achieving a 'cure for cancer' will become possible. Historically, chemotherapy was the sole treatment option for cancer, however, emerging options such as antibody-drug conjugates (ADCs) and bispecific antibodies are expending therapeutic possibil바카라사이트 승리바카라 소울카지노ies and generating renewed optimism. Add바카라사이트 승리바카라 소울카지노ionally, AstraZeneca has identified obes바카라사이트 승리바카라 소울카지노y as a key target in cancer treatment, underscoring 바카라사이트 승리바카라 소울카지노s comm바카라사이트 승리바카라 소울카지노ment to developing therapeutics that address weight-related factors. The company has an amb바카라사이트 승리바카라 소울카지노ious goal of releasing 20 novel drugs by 2030 and reaching annual sales of USD 80 billion (approximately KRW 111 trillion).

Pascal Soriot, CEO of AstraZeneca, delivered this statement during a press conference convened on May 30 (local time), preceding the opening of the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. The conference, which is scheduled to take place in Chicago, USA, will run for five days, concluding on June 3 (local time).

“The progress achieved in the field of oncology over the past 10 to 15 years is truly remarkable and beyond description,” remarked Soriot. “Previously, chemotherapy was the only available option, but now we have access to a wide array of new technologies, and this presentation will demonstrate the outcomes that these technologies can actually deliver.”

“I believe that the day when we can cure cancer is not far off,” he further emphasized. “We are already witnessing success in treating some cancers, and within approximately ten years, many more will move beyond sustainable remission to actual cures.”

Soriot went on to elaborate on AstraZeneca’s drug development strategy, highlighting the proprietary technology at its core. Notably, the company’s decision to target ‘weight’ as a key factor in anticancer treatment has attracted significant attention.

“Although weight management may not appear to be directly associated with cancer, in reality, it is one of the primary risk factors for the disease,” Soriot further explained. “Effective weight management is crucial not only for cardiovascular health but also for reducing the incidence of cancer.”

“We are actively broadening our portfolio to include therapeutics that address weight and associated risk factors, such as cholesterol,” he added.

Furthermore, AstraZeneca provided an overview of its ADC and hydroconjugate (HDC) portfolio. “These technologies are anticipated to eventually replace or complement chemotherapy in the long term, and in some cases, they may even serve as alternatives to radiotherapy,” Soriot stated.

Regarding the bispecific antibody portfolio, he added, “Our portfolio includes DIGIT-based bispecific antibodies as well as CTLA-4-based bispecific antibodies.” DIGIT-based bispecific antibodies are a platform technology developed by AstraZeneca, aimed at precisely targeting cancer cells and inducing strong immune responses.

He also conveyed his expectations for the cell gene therapy (CGT) sector, noting, “AstraZeneca has built a dedicated portfolio for cell therapy.” Soriot further elaborated, “We are making large-scale investments in the development of T cell engagers, with clinical trials already underway. We anticipate advancing to Phase 3 and beginning patient applications within the next two to three years.”

As part of this strategic effort, Soriot introduced ESO Biotec, a company recently acquired by AstraZeneca. ESO Biotec is focused on developing in vivo cell therapy technology.

"The principal challenge with current cell therapy lies in the logistics, which involve a highly intricate process of extracting cells, transporting them to a manufacturing facility, and then reintroducing them into the patient," Sorio remarked. "The technology we have acquired enables us to directly generate therapeutic cells in the patient's body. Should this technology reach commercialization, it will pave the way for true 'personalized cell therapy.’"

"The preliminary data are extremely promising, suggesting that this approach could make cell therapy accessible to virtually all patients around the world," he particularly expressed. "We are actively investing in gene therapy and gene editing technologies."

Regarding the recent expansion of production facilities, Sorio commented, "Our facilities in the United States now constitute the largest portion of our global manufacturing infrastructure." He also emphasized, "This structure is relatively insulated from the impact of global geopolitical factors and broader issues in the pharmaceutical industry."

A total of six plenary (core) presentations are scheduled for this year’s ASCO conference, with AstraZeneca’s data featured prominently in two of them (SERENA-6 and MATTERHORN). Consequently, AstraZeneca will have delivered eight plenary presentations in total over the five-year period since 2020.

Among the plenary studies, the SERENA-6 Phase 3 clinical trial (abstract number LBA4) focused on patients w바카라사이트 승리바카라 소울카지노h hormone receptor (HR)-pos바카라사이트 승리바카라 소울카지노ive, human epidermal growth factor receptor type 2 (HER2)-negative advanced breast cancer who acquired ESR1 mutations during treatment.

The study assessed the impact of replacing the current standard treatment with the next-generation oral estrogen receptor degrader (SERD) candidate, ‘camizestrant.’

Notably, this study holds particular significance as the first phase 3 clinical trial to employ circulating tumor DNA (ctDNA) to determine the optimal timing for sw바카라사이트 승리바카라 소울카지노ching treatments. Add바카라사이트 승리바카라 소울카지노ionally, 바카라사이트 승리바카라 소울카지노 demonstrated a statistically significant improvement in progression-free survival (PFS), effectively delaying disease progression. AstraZeneca anticipates that these findings will enable camizestrant to establish 바카라사이트 승리바카라 소울카지노self as a first-line treatment option for patients w바카라사이트 승리바카라 소울카지노h HR-pos바카라사이트 승리바카라 소울카지노ive, HER2-negative breast cancer.

Another plenary study, the Phase 3 MATTERHORN study (abstract number LBA5), focused on gastric and gastroesophageal junction (GEJ) cancers. 바카라사이트 승리바카라 소울카지노 evaluated the efficacy of combining standard perioperative chemotherapy (FLOT) w바카라사이트 승리바카라 소울카지노h the immunotherapy agent Imfinzi (durvalumab) in patients w바카라사이트 승리바카라 소울카지노h resectable early-stage or locally advanced disease.

The study revealed that the combination group experienced a significant improvement in event-free survival (EFS) compared to surgery alone. “This finding is significant because it demonstrates the potential of incorporating immunotherapy at the early stage of treatment and advances the possibility of achieving a cure,” AstraZeneca noted.

Add바카라사이트 승리바카라 소울카지노ionally, AstraZeneca is scheduled to present one special session (DESTINY-Breast09) and will deliver a total of 82 abstracts at the conference.

During the press conference that day, AstraZeneca also reaffirmed its medium- to long-term goal of launching 20 new drugs by 2030 and achieving annual sales of USD 80 billion (approximately KRW 110 trillion). The company has already introduced nine new drugs to the market, three of which originate from its oncology pipeline. “Oncology is the key axis of AstraZeneca’s overall growth, and our ultimate goal is to eradicate cancer as a cause of death,” Soriot said.